Isocitrate Dehydrogenase Gene Mutation clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • HMPL-306 in Advanced Hematological Malignancies With mIDH

    open to eligible people ages 18 years and up

    An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

    Orange, California and other locations

Our lead scientists for Isocitrate Dehydrogenase Gene Mutation research studies include .

Last updated: